Armata Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ARMP Armata Pharmaceuticals Inc
BAC Bank of America Corp
TNP Tsakos Energy Navigation Ltd
BFS Saul Centers Inc
ALNY Alnylam Pharmaceuticals Inc
VCNX Vaccinex Inc
XOM Exxon Mobil Corp
ETV Eaton Vance Tax-Managed Buy-Write Opportunities Fund
ASPI ASP Isotopes Inc
ADAG Adagene Inc

Health Care : Biotechnology | Small Cap Blend
Company profile

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using bacteriophage-based technology. It has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The Company is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. It is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The Company is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. It has phage development to target other indications, including non-cystic fibrosis bronchiectasis (NCFB), prosthetic joint infections (PJI) and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

Closing Price
Day's Change
-0.14 (-4.67%)
B/A Size
Day's High
Day's Low

10-day average volume:

Apollo, Sixth Street not part of of Elon Musk's Twitter debt deal: Reuters

7:53 am ET October 6, 2022 (MarketWatch)

Apollo Global Management Inc. and Sixth Street Partners LLC are not moving ahead with talks to help finance Elon Musk's $44 billion acquisition of Twitter Inc. , Reuters reported. Musk replied, "correct" on Twitter when answering queries about whether the two lenders are absent from the $7.1 billion in third-party equity financing package for the deal, the report said. The two lenders stopped talking with Musk over the summer, after he asked Twitter to drop the deal as proposed in April, Reuters said in its report, which was published on Wednesday. Earlier this week, Musk changed course again and decided to move ahead with the acquisition. The banks that initially agreed to provide debt for the deal in the spring could face "significant losses" when they sell the debt due to much less favorable financing conditions currently, Reuters also reported. Major banks including Morgan Stanley , Bank of America Corp. , Barclays , Societe Generale S.A. , Mitsubishi UFJ Financial Group Inc , BNP Paribas SA , and Mizuho Financial Group Inc s[: jp:8411] have committed $12.5 billion to finance Musk' acquisition of Twitter.

-Steve Gelsi


(END) Dow Jones Newswires

October 06, 2022 07:53 ET (11:53 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.